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Prostate cancer is one of the most common types of cancer in western country
males but the mechanisms involved in the transformation processes have not been
clearly elucidated. Alteration in cellular metabolism in cancer cells is recognized as a
hallmark of malignant transformation, although it is becoming clear that the biological
features of metabolic reprogramming not only differ in different cancers, but also among
different cells in a type of cancer. Normal prostate epithelial cells have a peculiar and
very inefficient energy metabolism as they use glucose to synthesize citrate that is
secreted as part of the seminal liquid. During the transformation process, prostate
cancer cells modify their energy metabolism from inefficient to highly efficient, often
taking advantage of the interaction with other cell types in the tumor microenvironment
that are corrupted to produce and secrete metabolic intermediates used by cancer
cells in catabolic and anabolic processes. We recapitulate the metabolic transformations
occurring in the prostate from the normal cell to the metastasis, highlighting the role of
the microenvironment and summarizing what is known on the molecular mechanisms
involved in the process.
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Alterations in cancer cell metabolism have been considered for years a secondary effect in the
complex picture of tumor biology in spite of the unequivocal evidence that changes in cell function
always require changes in cell metabolism. Recently, important studies focused the attention on
the cellular pathways responsible for energy production and synthesis of molecules, both required
to sustain the replication of cells that are growing uncontrolled. As a consequence, new promising
therapeutic targets are emerging.
The proliferation of normal cells is controlled by the presence of growth factors in the
microenvironment and by the interaction with other cells; oxygen and nutrients are provided by
the blood. Transformed cancer cells acquire the ability to proliferate in absence of growth factors
and to ignore the antiproliferative stimuli like for example those mediated by cell-to-cell contacts.
Cancer cell proliferation, per se, moves the cells away from the blood vessels and therefore from
oxygen and nutrients generating a hypoxic and nutrient-poor microenvironment. The adaptation
Abbreviations: Pca, Prostate cancer; PIN, prostate intraepithelial neoplasia; OXPHOS, oxidative phosphorylation; HIF1α,
hypoxia inducible factor 1α; m-aconitase, mitochondrial aconitase; CAFS, cancer-associated fibroblasts; DEC1, deleted in
esophageal cancer 1; PKM2, Pyruvate kinase M2; MCTs, monocarboxylate transporters; CAIX, carbonic anhydrase IX; FDG-
PET, FluDeoxyGlucose-Positron Emission Tomography; TLR4, Toll like receptor 4; TNFα, Tumor Necrosis Factor-α; TN
breast cancer, Triple Negative breast cancer.
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of cancer cells to the novel situation implies a profound
reprogramming of metabolism, largely affecting pathways
involving the key metabolic substrates (such as glucose, but
not only) and redox homeostasis. Among cell’s organelles,
mitochondria witness large functional changes, which reflect the
novel needs of the cancer cells. Paradoxically several cancer cell
types show a very high glycolytic rate, and pyruvate is not used
in these cells for the Krebs cycle but transformed into lactate as a
waste product in the so-called Warburg effect (Warburg, 1956),
generating a very small amount of energy with respect to the
complete respiratory process potential. Lactate fermentation is
often used in normal cells under hypoxic conditions, but cancer
cells use this metabolic pathway independently from oxygen
availability. The reason for this metabolic switch in cancer cells
is not entirely clear, in particular considering its low energetic
efficiency, and it has been hypothesized that this pathway is used
to produce metabolic intermediates needed in anabolic processes
fundamental for cancer cells.
Prostate cancer is the second most common type of cancer
in western country males (Siegel et al., 2016). Fortunately, 80%
of patients with an early diagnosis have a very good prognosis
and radical prostatectomy is still the most diffused approach
with a high rate of success and no side effects. However, the
prognosis becomes worse if the diagnosis is tardive and the
disease becomes metastatic. Cancer lesions can develop in two
different regions of the prostate gland, most commonly (80%)
in the periphery zone; the remaining lesions are found in the
transition zone, which is located in the periurethral region
(McNeal, 1988).
The prostate has a peculiar and unique metabolism that
changes during tumor onset and progression from the prostate
intraepithelial neoplasia (PIN) to metastasis (see Table 1). This
is in agreement with the current opinion on the heterogeneity
of metabolism remodeling in cancer cells (Strickaert et al.,
2016). This scenario is further complicated by the interaction
between prostate cancer cells and other cell types present in
the microenvironment, such as immune cells, fibroblast or
adipocytes in the metastasis, actively participating in tumor
metabolism. In this review we will recapitulate the metabolic
transformations of glucose metabolism that occur from normal
prostate epithelium to themetastatic microenvironment focusing
on the molecular events that are or could be responsible for these
alterations.
TABLE 1 | Metabolic alterations in prostate, breast and liver cancer cells.
Prostate Breast Liver
Normal cells Cancer cells Metastatic cells Triple negative Estrogen positive Cancer cells
Ox Phos Inactive Active Inactive Inactive Active Inactive
Krebs cycle Inactive Active Inactive Inactive Active Inactive
Glucose Consumed Consumed Consumed Consumed – Consumed
Lactate – Consumed Accumulat. Secreted Imported Secreted
Citrate Secreted Consumed – – Consumed –
The main metabolic alterations of glucose metabolism in prostate, breast (TN and estrogen positive) and liver cancer cells are summarized (Elia et al., 2016).
CITRATE METABOLISM IN PROSTATE
EPITHELIAL CELLS
One of the main functions of the prostate gland is to produce and
secrete large amounts of citrate, which is released from epithelial
cells into the lumen (Figure 1). Citrate production is obtained
through the activity of a specific type of glandular epithelial cells
and is not observable in any other kind of cells. The metabolism
of prostate epithelial cells is modified for this special function.
In the mitochondria of most mammalian cells, the pyruvate
produced by glycolysis is decarboxylated to generate Acetyl-CoA,
which reacts with oxalacetic acid to produce citrate that is then
oxidized through the Krebs cycle. On the other hand, in normal
prostate epithelium, mitochondrial citrate oxidation is impaired,
mainly by inhibition of mitochondrial aconitase (m-aconitase),
the enzyme responsible for the first step of transformation of
citrate in the Krebs cycle (see also below): in these cells, citrate
is thus the final product of the glucose metabolism and not
an intermediate (Costello and Franklin, 2006). Differently from
other cells in which, at the end of the Krebs cycle, oxalacetic
acid is regenerated, in prostate cells this is not possible and
oxalacetic acid is produced from aspartate that is imported from
the plasma through the specific receptor excitatory amino acid
carrier 1 (EAAC1) (Franklin et al., 2006). It has been clearly
demonstrated that, in prostate cells, Krebs cycle is essentially
inhibited so these cells are energetically inefficient. Prostate cells
therefore show a very low level of oxidative phosphorylation
(OXPHOS), counterbalanced by an increased glycolitic rate to
survive and sustain the citrate production.
As a substrate for Krebs cycle, citrate represents an attractive
source of energy for a transformed prostate cell, which has an
increased energy demand. Franklin and Costello proposed “the
bioenergetic theory of prostate malignancy”: the observation
of very low levels of citrate in prostate cancer led to the
hypothesis that malignant cells, in order to resume an efficient
energy-generating system, become able to oxidize citrate in
order to produce ATP, thus completing the Krebs cycle and
transforming a healthy metabolically-inefficient prostate cell into
an energy efficient malignant cell (Figure 1). These authors also
concluded that this alteration is an early event in the malignant
progression, which even precedes the histological identification
of the malignant cells (Cooper and Farid, 1964; Costello et al.,
1997; Costello and Franklin, 2000).
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FIGURE 1 | Metabolic alteration in the tumor microenvironment during prostate cancer progression. Normal prostate epithelial cells have a peculiar
metabolic profile, the Krebs cycle and the OXPHOS are inhibited and the citrate is released as component of the seminal liquid. Prostate cancer cells corrupt cancer
associated fibroblasts (CAFS) to activate the Warburg effect and to secrete lactate that is used by cancer cells for anabolic and catabolic processes, CAFS, in turn,
induce OXPHOS activation in cancer cells. Prostate cancer cells preferentially metastasize in the bone. Cancer cells stimulate lypolisys in the adipocytes that secrete
glycerol; adipocytes, in turn, stimulate the Warburg effect in cancer cells. Glycerol uptake and consumption by cancer cells has been described elsewhere, but it has
not been demonstrated in this model.
As previously mentioned, the inhibition of the Krebs cycle
in normal prostate cells, resulting in the accumulation and
subsequent secretion of citrate, is mainly obtained through
the inhibition of m-aconitase, due to the accumulation of
zinc in these prostate cells (Costello and Franklin, 2006).
Citrate concentration in normal prostate cells is around 12-
fold higher with respect to blood plasma levels, reaching the
extraordinary concentration of about 13,000 nanomoles per
gram of wet tissue. Zinc concentration is possibly even higher,
reaching the concentration of about 4,000 nanomoles per gram
that is around 200-fold higher with respect to blood plasma
concentration. Zinc accumulation in the mitochondria truncates
the Krebs cycle by inhibiting m-aconitase and determining
the peculiar metabolism of normal prostate cells (Costello
and Franklin, 2006). It has been observed that zinc levels
are dramatically reduced in prostate cancer cells (Tsui et al.,
2006), inducing the reactivation of m-aconitase and of the
Krebs cycle. These data are supported by the observation
that also citrate concentration is strikingly reduced in prostate
cancer cells. If normal prostate cells sacrifice 60% of the
energy producing 14 ATP molecules per glucose molecule,
prostate cancer cells, which completely oxidize citrate, produce
additional 24 ATP molecules becoming energetically highly
efficient.
Other than inhibiting m-aconitase, zinc produces other
important effects. Zinc is responsible for apoptotic induction in
prostate cancer cells, by inducing the release of cytocrome c from
mitochondria, activating the caspases cascade and inhibiting
the antiapoptotic protein NF-κB (Feng et al., 2002; Uzzo et al.,
2002; Huang et al., 2006). Invasive and proangiogenic capabilities
of metastatic prostate cancer cells are also inhibited by zinc
subministration (Uzzo et al., 2006). Considering the anti-tumor
effects of zinc administration in the cellular models a very
recent review suggested to use zinc for the treatment of prostate
and other type of cancer that exhibit zinc reduction (Costello
and Franklin, 2017). Zinc uptake from the interstitial fluid in
normal prostate cells is probably due to the activity of the
zinc transporters hZIP1 and hZIP3 (Franklin et al., 2003).
Interestingly the hZIP1 protein is expressed at a lower level
in the prostate epithelium of afro-american men compared
to the caucasian population, which could partially explain the
higher susceptibility of afro-american population to prostate
cancer (Rishi et al., 2003). The study demonstrated that hZIP1
downregulation in prostate malignant tissue is associated with
reduced zinc concentration in the same area. Recent studies
clarified the mechanism of zinc transporters downregulation
in prostate cancer. Makhov et al. demonstrated that AP-
2a, a transcription factor responsible together with AP-1 for
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hZIP1 and hZIP3 transcription is epigenetically silenced through
promoter hypermethylation in DU145 and LNCaP cell lines
(Makhov et al., 2011). This suggests that the efficacy of the
drugs that inhibit promoter hypermethylation, like 5-azacytidine,
observed in prostate cancer cells, can be due to the reactivation of
genes involved in cancer cell metabolism like hZIP1 and hZIP3.
LACTATE SHUTTLING AND THE TUMOR
MICROENVIRONMENT
For each step in cancer progression, cells need to readjust
bioenergetics and metabolism to sustain the new status. If citrate
oxidation transforms highly inefficient prostate cells in more
efficient transformed cells, we should consider that, being citrate
oxidation a central metabolic process in normal non-prostatic
cells, this adjustment is necessary but not sufficient for a cell to
become really tumoral. Transformed prostate cells need an extra
input in terms of energy or availability of molecular backbones
for the anabolic processes. A critical step forward in malignant
progression might be controlled by the interaction with and
the support of other cells in tumor microenvironment, which
may provide metabolic substrates (as lactate, see below) to be
channeled by cancer cells into energy-producing and/or anabolic
pathways.
For many years, studies on cancer metabolism have
been focused specifically on cancer cells using homotypical
populations. Otto Warburg, the pioneer of these studies,
suggested to use homogeneous cell populations, like those
obtained from ascites fluid, to obtain reliable results and
probably he influenced for decades the approach to this kind
of experiments. More recently, several studies demonstrated the
importance of the compartmentalization and heterogeneity in
tumor microenvironment, also relatively to metabolism. In this
complex scenario, in the same tumoral mass, some cancer cells
seems to be highly glycolitic, others have higher mitochondrial
respiration rates (Sonveaux et al., 2008). Moreover other cell
types, like cancer-associated fibroblasts (CAFS), can directly
participate to the complex metabolic mechanism particularly
in prostate cancer (Figure 1). Fibroblasts are the second most
abundant cell population in the tumormass. It has been proposed
that these cells would be an important source of lactate to be
imported into cancer cells to produce pyruvate or to fuel anabolic
processes. Lactate is normally considered a waste product, but
surprisingly, in 2008, Sonveaux et al. demonstrated in several
cancer models with a particularly active OXPHOS that this
molecule is preferred to glucose and that lactate uptake and
consumption influence key functions in cancer cells like redox
homeostasis and angiogenesis (Sonveaux et al., 2008; Dhup et al.,
2012).
Transformed prostatic cells use IL-6 secretion to corrupt
fibroblasts (Doldi et al., 2015). Tumor epithelium may also
promote the downregulation of the tumor-suppressor p62 in
stromal fibroblasts, leading to a decrease in mTORC1 activity
and c-Myc expression, in turn producing impairment in the
mechanism of metabolic detoxification and the subsequent
release of ROS and IL-6. An autocrine loop promotes TGF-β
and the induction of CAF phenotype, which further increases
epithelial invasion and tumorigenesis (Valencia et al., 2014).
“Activated” fibroblasts would turn on the Warburg effect
increasing glucose consumption and generating large amounts
of lactate that is secreted in the microenvironment as a “waste
product.” The effect of CAFS on tumor cells involves Pyruvate
kinase M2 (PKM2) activation. Exposure of prostate cancer cells
to CAFS induces phosphorylation and oxidation of PKM2;
after modification, the protein loses its metabolic function and
acquire the ability to migrate into the nucleus, to interact
with the hypoxia inducible factor 1α (HIF1α) and the protein
DEC1, to inhibit transcription of a specific microRNA (mir-
205) driving the metabolic conversion to OXPHOS of prostate
cancer cells (Fiaschi et al., 2012; Giannoni et al., 2015). A
similar mechanism has been described also in immune cells.
In macrophages, after Toll like receptor 4 (TLR4) stimulation,
HIF1α and the “inactive” form of PKM2 interact to induce
a metabolic switch, yielding a completely different effect than
that observed in prostate cancer cells, as macrophages acquire a
Warburg-like phenotype necessary for their complete activation
(Palsson-McDermott et al., 2015). These data indicate that,
although the basic mechanism involved in the metabolic switch
controlling Warburg/OXPHOS is common to different cell types
and scenarios, molecular adaptors selectively expressed in each
cell type in the specific context determine the final output.
MONOCARBOXYLATE TRANSPORTERS IN
PROSTATE CANCER
Although with some discrepancy, it is commonly accepted that
an important role in CAFS interaction with prostate cancer
cells is fulfilled by monocarboxylate transporters (MCTs). MCT
family is composed by 14 members, but only for 4 transporters
(MCT1-4) a role in the transport of monocarboxylate molecules
has been demonstrated. MCTs translocate across the plasma
membrane a monocarboxylate molecule together with a proton
with no direct energy input. As consequence, MCT activity is
dependent on substrates concentration and proton gradient (Juel,
1997). Whereas MCT3 is specifically expressed in the retina
and in the choroid plexus, MCT1, MCT2 and MCT4 have been
demonstrated to transport important monocarboxylates like
lactate, pyruvate, ketone bodies (acetoacetate, β-idroxybutyrate)
in several tissues including prostate cancer (Halestrap and
Price, 1999; Pértega-Gomes and Baltazar, 2014). During prostate
cancer progression, the expression profile of MCT isoforms
changes (Pértega-Gomes and Baltazar, 2014). MCT1 is expressed
in normal and malignant prostate, MCT2 increases from
normal gland to PIN and in situ carcinoma. On the other
hand, MCT4 is only expressed in malignancy. While MCT1
and 2 transport a wider range of substrates, MCT4 role is
specifically associated with the export of lactate in cells with
high glycolytic rate. Recently Pértega-Gomes et al. (2014)
performed an immunohistochemical analysis on 480 samples
from prostate cancer patients studying the expression of
MCTs and other metabolic proteins. They observed important
differences between CAFS and cancer cells. MCT4 and carbonic
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anhydrase IX (CAIX) were preferentially expressed on CAFS, by
contrast MCT1 was expressed specifically on tumor cells. These
data suggest that MCT1 could be responsible for lactate uptake
in cancer cells from the acidic microenvironment; the import
of lactate helps to regenerate NADH and accelerate glycolysis.
Unfortunately, since the authors could not demonstrate the
presence of glucose transporters on CAFS, thus the final
demonstration of this mechanism is still missing.
WARBURG EFFECT IN PROSTATE
CANCER METASTASIS
Metastatization, the process by which cancer cells leave the
original tumor site and migrate to other parts of the body, is
probably the most complex. Over and above than acquiring
the capability to escape from the primary tumor detaching
from the rest of the tissue, digesting the matrix and invading
the circulation, the cells spend time and “efforts” to learn
how to survive in a novel, possibly hostile, microenvironment.
The dissemination in a new context needs new and dramatic
adaptations requiring several new metabolic competencies.
Differently to the primary tumor, the metabolic mechanisms
that sustain the growth of prostate cancer metastasis have not
been clearly elucidated, the androgen signaling seems to be
involved in some extent particularly in androgen sensitive cells
LNCaP and VCaP inducing both glycolysis and OXPHOS, but
the molecular mechanisms and the cellular context have been
only partially elucidated (Tennakoon et al., 2014). In contrast
to other cancer cell types that develop a higher level of glucose
consumption early in the transformation process, prostate cancer
cells switch to the Warburg effect only in the metastatic stage,
excluding the possibility to use advanced diagnostic procedures
like standard FDG-PET scan for the detection of tumor in the
early stages (Schöder and Larson, 2004; Testa et al., 2016).
The prostate, together with lung and breast are the most
frequent sites of primary tumors, but cancer cells from these sites
share another important characteristic, as they can disseminate
in the bone and bone metastasis represents an indication of poor
prognosis (Mundy, 1997). The 1-year mortality is dramatically
higher in prostate cancer patients with bone metastasis with
respect to those with no skeletal involvement (Nørgaard et al.,
2010). The new microenvironment means also new interactions
with new cell types that need to be corrupted in order to sustain
tumor growth.
The adipocytes are the most abundant cells in the bone
marrow (Hardaway et al., 2014): the number of these cells
grows together with the risk of metastatic prostate cancer
with age, obesity and metabolic disorders (Justesen et al.,
2001; Strotmeyer and Cauley, 2007). Moreover, the adipocytes
are highly metabolically active cells, able to promote tumor
growth and increased aggressiveness of cancer cells that grow
as bone metastasis (Justesen et al., 2001; Herroon et al., 2013;
Templeton et al., 2015). Very recent studies reported that
the adipocytes could be responsible for the switch to the
Warburg effect of prostate cancer metastatic cells, being able
to modulate metabolism as shown for CAFS in the primary
tumor. Prostate cancer cells co-cultured with adipocytes switch
to a high glycolytic rate, increasing HIF1α production in an
oxygen independent manner. HIF1α accumulation is responsible
for the transcription of the Warburg related genes, resulting
in lactate accumulation and OXPHOS inhibition. Using the
stimulation with conditioned media (CM), the authors clarified
that the physical interaction between cancer cells and adipocytes
is not necessary; however, they failed in the identification of
the soluble factor(s) responsible for the switch. Interestingly,
prostate cancer cells (Pca) exposed to the adipocyte CM alone
do not switch to the Warburg metabolism, while, using the
conditionedmedia from the Pca/adipocyte co-culture, a dramatic
metabolic reprogramming occurs in Pca cells. On the other hand,
adipocytes treated with Pca CM increase the levels of the adipose
triglyceride lipase (ATGL) the key enzyme in the lipolytic process
and secrete large amount of free glycerol, suggesting a Pca-
induced lipolytic phenotype (Diedrich et al., 2016). Although it
has not been directly demonstrated in this model, it is known
that glycerol can enter in the glycolytic process and feed cancer
cells (Vaughan, 1962; Langin, 2006; Maeda et al., 2008). Overall
these data validate the idea that Pca cells corrupt the other cells in
the microenvironment to generate metabolic intermediates that
are in turn used by cancer cells. Thus, the microenvironment
metabolically sustains the growth of the tumor, creating a specific
niche in which cancer cells can survive and proliferate.
PROSTATE CANCER AND INFLAMMATION
About 20% of all human cancers are caused by chronic infection
or chronic inflammatory states (De Marzo et al., 2007). Some
of the roles of both innate and adaptive immunity in cancer
progression have been clarified (Kim et al., 2009) but the
complete mechanism is far from being elucidated. Although
several criticisms have been raised on the detection protocols, a
large number of clinical studies underline a positive correlation
between recurrent prostatitis and prostate cancer (De Marzo
et al., 2007). Unfortunately, the possible microorganism(s)
or inflammation-generating factor(s) that should produce the
chronic inflammatory status still remain elusive (Sfanos and
De Marzo, 2012). A recent paper proposed a link between the
immune system and the metabolic reprogramming of prostate
cancer cells. Vaughan et al. (2013) describe the ability of the
inflammatory factor Tumor Necrosis Factor α (TNFα) to induce
a HIF1α-dependent metabolic switch in prostate cells, inducing
aerobic glycolysis and blocking the OXPHOS mechanism. The
authors in this study used the canonical prostate cancer cells
lines LNCaP and PC3, but also tested RWPE cells that are
commonly considered normal prostatic epithelium. As described
before, metastatic cancer cells seem to acquire characteristics
that predispose to the Warburg effect and in some manner this
correlates with their ability to activate the aerobic glycolysis
after TNF stimulation; surprisingly however, also RWPE show
a Warburg phenotype after TNF stimulation (Vaughan et al.,
2013). These data, if confirmed, would suggest a completely
different track leading to metabolic reprogramming for those
prostate cancer cells arising as a consequence of the chronic
inflammatory status: in the inflammation-driven tumorigenesis,
the Warburg phenotype would indeed be induced at the
beginning of the transformation process (Figure 2). These would
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FIGURE 2 | Hypothetical mechanism of inflammation-induced cancer
feeding. The cytokines are released by infected cells and induce the Warburg
effect in a different subpopulation, the lactate secreted would be used by
transformed cells for anabolic and catabolic processes as described by
Sonveaux et al. (2008).
permit the identification of a new subset of patients that should be
treated differently from the others maybe with anti-inflammatory
therapies associated with the inhibition of glycolysis.
CONCLUDING REMARKS AND OPEN
QUESTIONS
The number of prostate cancer cases around the world is
increasing. The incidence of this tumor has been associated with
aging, environmental factors and changes in lifestyle. While it
is becoming clear that a profound metabolic reprogramming
occurs in prostate cancer cells, the majority of the molecular
mechanisms involved in the process remain to be elucidated
and are likely to be complex, encompassing changes within the
prostate epithelial cells and crosstalk with other cell types present
in the microenvironment. Although some data are available
on the reshape of energy and carbohydrate metabolism, other
metabolic pathways remain underinvestigated, as for example
those involving amino acids (glutamine, serine) and fatty acids,
as their control by epigenetic mechanisms, the latter proven to
be important in many cancer types (Wong et al., 2017). Future
research in the field of prostate cancer metabolism will also have
to deal with elucidation of the interplay between inflammation
and oncogenesis. There are also evidences that the metabolic
reprogramming might follow different routes if inflammation-
driven. The possible soluble signals coming from the pathogens
leading to transformation of prostate epithelial cells are yet
unknown as is their influence on the metabolism of epithelial
cells or on inflammatory pathways in immune cells present in
tumor microenvironment, which may contribute to speed up the
malignant transformation.
The knowledge of themetabolic pathways and their regulation
in prostate cancer will help to identify possible targets that
can be exploited to device novel therapeutic strategies against
prostate cancer. These targets could include proteins as glucose
transporters, PKM2, the monocarboxylate trasporter MCT4 or
the ZIP1 zinc transporter, as well as novel players to be identified
in the next future.
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